2-year survival outcomes of atezolizumab plus bevacizumab as first-line treatment for patients with metastatic nonsquamous non-small cell lung cancer with high tumor mutation burden: TELMA trial final report
Por:
Pulla M, Granados A, Sarto J, de Juan V, Fabregat R, Gomez M, Guirado M, Carcereny E, Nunez N, Cabellos R, Guerrero R, Mateos L, Torres J, Sureda B, Sullivan I, Dols M, Hernandez A, Cabrera C, Cruz-Bermudez A
Publicada:
1 mar 2025
Resumen:
|